Business
First CE marked release of TexRAD® technology
First CE marked release of TexRAD® technology.
About this update from Feedback Plc
[{"type":"text","content":"\n \nRNS Number : 9059W Feedback PLC 20 November 2017 \n\n \nThis announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 (MAR).\n \nFeedback plc\n(\"Feedback\" or the \"Company\")\n \nFirst CE marked release of TexRAD® technology\n \nFeedback plc (AIM: FDBK), the specialist medical imaging technology company, announces the first CE marked release of TexRAD®; the Company's patented quantitative image texture analysis technology for diagnostic radiological scans.\n \nTexRAD® has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. Feedback's subsidiary company, Cambridge Computed Imaging Ltd, has affixed a CE mark to \"TexRAD® Lung\"; a \"software only\" Class 1 medical device providing additional information for the interpretation of computerised tomography (CT) and positron emission tomography (PET) scans of patients with lung cancer. The CE mark confirms that TexRAD® Lung meets the requirements of the Medical Device Directive (MDD - 93/42EEC) ensuring the technology satisfies the quality, safety and performance standards for medical devices in the European Union (EU).\n \nLung cancer has been the most common cancer in the world for several decades, estimated at 13% of all cancer diagnoses globally. It is also the most common cause of death from cancer worldwide, estimated to be responsible for nearly one in five. In the EU alone there are approximately 417,000 new cases of lung cancer every year. Radiologists are under significant pressure due to increasing patient numbers, more examinations required per patient and the need for earlier diagnosis. By analysing the texture features in CT scans, TexRAD®'s quantitative imaging capabilities provide clinicians with additional information to make better decisions in order to improve patient outcomes.\n \nDr Alastair Riddell, Chairman at Feedback plc, said: \"TexRAD® Lung is our first TexRAD® product with a CE mark which represents a significant accomplishment. This development will expedite TexRAD®'s clinical use in the treatment of lung cancer across the EU, expand its market prese...